Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their applications from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways of Small Nucleic Acid Drug Development - ASO and siRNA represent two distinct technological pathways, with ASO focusing on RNA degradation and splicing regulation, while siRNA employs the RISC mechanism for mRNA degradation [12][26] Chemical Modifications and Stability - The report outlines four generations of chemical modifications that enhance the stability and specificity of ASO, which are crucial for their therapeutic efficacy [32][36] Delivery Breakthroughs - The report identifies the challenges of delivering small nucleic acids across cellular barriers, emphasizing the need for effective delivery systems to overcome these obstacles [40][43] Safety Optimization - Innovations in safety management, such as the development of antidotes for siRNA and toxicity control for ASO, are essential for supporting long-term use and chronic disease management [3][62] Commercialization and Boundary Expansion - The industry is moving from liver-targeted therapies to exploring delivery strategies for other tissues, with companies like Alnylam aiming for multi-organ delivery by 2030 [60][61]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the ongoing collaboration between GSK and Chinese company Frontier Bio in the siRNA field, indicating that Chinese enterprises are gaining international recognition for their R&D capabilities [6][7] - The pharmaceutical sector saw a 0.5% increase, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th among 31 sub-industries [8][22] - The report recommends focusing on innovative drugs and their supply chains, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [9] Summary by Sections GSK Collaboration and Market Trends - GSK has been actively engaging in partnerships related to small nucleic acids, with significant pipelines in ASO and siRNA. Notably, GSK's collaboration with Frontier Bio involves a total transaction value of up to $1.003 billion for two pipelines [6][7][18] - The report notes that GSK's recent partnerships reflect the growing technical strength and platform value of Chinese companies in the small nucleic acid drug development sector [7][17] Market Performance - In the week of February 4, 2026, the pharmaceutical sector increased by 0.5%, with the medical consumables sector showing the highest growth at 3.99%. Conversely, the medical R&D outsourcing sector experienced the largest decline at -2.2% [8][22][23] - Monthly data indicates that since the beginning of 2026, the overall market has been on an upward trend, with various sectors performing differently [22] Recommendations - The report continues to favor innovative drugs and their associated industries, recommending specific companies such as Heng Rui Medicine, WuXi AppTec, and others for investment [9][26] - Weekly recommendations include companies like Bai Li Tian Heng and Kanglong Huacheng, indicating a strategic focus on firms with strong growth potential in the pharmaceutical sector [9]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the ongoing collaboration between GSK and domestic companies in the siRNA field, indicating that Chinese enterprises are gaining international recognition for their R&D capabilities [6][7] - The pharmaceutical sector has shown a 0.5% increase, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th among 31 sub-industries [8][22] - The report emphasizes the positive outlook for innovative drugs and their supply chain, recommending specific companies for investment [9] Summary by Sections GSK Collaboration and R&D - GSK has been actively collaborating in the small nucleic acid space, with multiple significant pipelines. Since 2009, GSK has engaged in numerous business development transactions focused on ASO and siRNA [6][16] - In 2026, GSK partnered with a Chinese siRNA company, Frontline Bio, for a deal worth up to $1.003 billion, showcasing the growing recognition of Chinese firms in the global market [7][18] Market Performance - The pharmaceutical sector's performance in February 2026 showed a 0.5% increase, with the medical consumables sector leading with a 3.99% rise, while the medical R&D outsourcing sector experienced the largest decline at 2.2% [22][23] - Monthly data indicates that the overall market has been on an upward trend since the beginning of 2026, with various sectors performing differently [22][26] Investment Recommendations - The report maintains a positive outlook on innovative drugs and their supply chain, including CXO and research services, as well as emerging industries like AI and bio-manufacturing [9] - Monthly and weekly investment recommendations include companies such as Heng Rui Medicine, WuXi AppTec, and Frontline Bio, among others [9]

Summary of siRNA Drug Industry Conference Call Industry Overview - The siRNA drug industry is gaining traction as a prominent direction in new drug development due to its ability to precisely silence pathogenic proteins, offering high degradation efficiency and prolonged action time compared to traditional small molecules and biologics [1][1] - The core technology in siRNA drugs is delivery, with a focus on extrahepatic delivery as the current breakthrough area. Various delivery methods include LNP, antibodies, peptides, and VLP, each with its advantages and disadvantages, with AOC showing slightly faster development [1][1] Key Insights - Major international players in the siRNA industry, such as Alnylam, have reached a harvest period with their GalNAc liver delivery system, which is recognized for its high delivery efficiency, strong specificity, and lasting effects. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization targeting cardiovascular common targets like PCSK9, AGT, Lp(a), and ApoC3 [1][1] - Research on extrahepatic organs such as muscles, the nervous system, and eyes is still in early development stages. Alnylam's C16 delivery platform has shown potential in the CNS field, while Arrowhead's TRiM platform has shown promise in adipose tissue, indicating that the discovery of new targets and extrahepatic delivery platforms will be core competitive points in the future [1][1] Domestic Market Dynamics - The domestic siRNA drug development landscape is characterized by a diverse array of startups, with Big Pharma also entering the market. Domestic companies have become significant players in the global siRNA arena, especially as many chronic disease drugs approach the end of their sales lifecycle, necessitating new technological iterations [2][2] - There is a strong business development willingness among multinational corporations (MNCs) in the liver delivery sector, with collaborations established between companies such as 舶望 and Novartis, 圣因 and Roche, 瑞博 and Madrigal, and 前沿 and GSK [2][2] - Domestic enterprises are actively pursuing dual-target and extrahepatic delivery strategies, gradually narrowing the gap with overseas competitors and potentially leading the industry development direction in the future [2][2] Investment Recommendations - Recommended stocks to watch include: - A-shares: 恒瑞医药, 必贝特, 前沿生物, 悦康药业, 阳光诺和, 福元医药 - Hong Kong stocks: 瑞博生物, 石药集团, 中国生物制药, 靖因药业 (already filed for listing) [3][3] - Risk factors to consider include: 1. Clinical progress of innovative drugs not meeting expectations 2. Clinical data of innovative drugs not meeting expectations 3. Sales performance of innovative drugs post-launch not meeting expectations 4. Geopolitical risks [3][3]

Group 1 - The core advantage of siRNA drugs lies in their ability to precisely silence pathogenic proteins, with delivery systems being the key technology [1] - siRNA therapies are gaining popularity in new drug development due to their high efficiency in degrading proteins and prolonged action time compared to traditional small molecules and biologics [1] - The focus of technological breakthroughs is on extrahepatic delivery, with various delivery methods such as LNP, antibodies, peptides, and VLP, each having its own advantages and disadvantages [1] Group 2 - Overseas giants like Alnylam have entered a harvest phase with their GalNAc liver delivery platform, which is recognized for its high efficiency and specificity [2] - Other companies such as Arrowhead and Dicerna are advancing siRNA drugs targeting common cardiovascular markers and are in late-stage clinical or commercial phases [2] - Research on extrahepatic delivery for muscle, nervous system, and ocular targets is still in early development, with potential seen in Alnylam's C16 platform and Arrowhead's TRiM platform [2] Group 3 - Domestic siRNA drug development is flourishing, with a variety of directions from startups and major pharmaceutical companies entering the field [3] - Collaborations between domestic companies and multinational corporations (MNCs) are increasing, with notable partnerships established with Novartis, Roche, and GSK [3] - Domestic firms are actively pursuing dual-target and extrahepatic delivery strategies, narrowing the gap with overseas competitors and potentially leading industry development [3]

Investment Rating - The industry investment rating is "Strong Outperform" and is maintained [1] Core Insights - siRNA drugs have significant mechanism advantages, with delivery as the core technology. Compared to traditional small molecules and biologics, siRNA drugs can precisely silence pathogenic proteins, degrade effectively, and have a long duration of action, making them a popular direction for new drug development. The core technology focuses on modification and delivery, with liver-external delivery being the current breakthrough focus [2][12] - Overseas giants are entering a harvest period, awaiting proof of concept (POC) for liver-external delivery. Alnylam's GalNAc liver-internal delivery has become the "standard answer" due to its high delivery efficiency and specificity. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization for cardiovascular targets, while liver-external organ targets are still in early development [3][41] - Domestic siRNA drug development is flourishing, with various directions from startups and major pharmaceutical companies. Domestic firms are becoming significant players in the global siRNA arena, with strong business development (BD) willingness from multinational corporations (MNCs) in the liver delivery space. New directions include dual-target and liver-external delivery, narrowing the gap with overseas competitors and potentially leading the industry [4] Summary by Sections siRNA Drug Mechanism Advantages - siRNA drugs can precisely silence pathogenic proteins and have a long duration of action, making them a hot direction for new drug development. The mechanism relies on the RISC complex to degrade target mRNA, with a typical structure of double-stranded RNA [10][12] - The delivery system is crucial for siRNA drug development, as siRNA is hydrophilic and requires specific delivery systems to enhance tissue accumulation and cellular penetration [23][24] Overseas Giants Entering Harvest Period - Alnylam is a pioneer in the siRNA industry, having developed the GalNAc delivery system, which has proven effective in human trials. The company has successfully commercialized several products and is expanding its pipeline in cardiovascular, metabolic, and CNS fields [43][53] Domestic siRNA Drug Development - Domestic companies are actively participating in the siRNA market, with collaborations with MNCs and a focus on innovative delivery methods. The investment recommendation includes companies like HengRui Medicine, Beite, and others in the A-share market, as well as several in the Hong Kong market [4]

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]

Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]